<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="//www.pharmaron.com/video-sitemap.xsl"?>
<urlset xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd http://www.google.com/schemas/sitemap-video/1.1 http://www.google.com/schemas/sitemap-video/1.1/sitemap-video.xsd" xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:video="http://www.google.com/schemas/sitemap-video/1.1">
	<url>
		<loc>https://www.pharmaron.com/knowledge-center/dmpk-webinar-37-adme-study/</loc>
		<video:video>
			<video:title><![CDATA[What Makes a Good ADME Study? Key Considerations for Radiolabelled and 14C Studies]]></video:title>
			<video:publication_date>2026-09-23T12:27:00-07:00</video:publication_date>
			<video:description><![CDATA[DMPK Webinar Series episode 37, recorded live on 22 September 2026 and available on demand. Designing a successful radiolabelled absorption, distribution, metabolism and excretion (ADME) study takes careful planning, from selecting the optimal 14C label position through to generating meaningful metabolism and mass balance data. A panel of experienced ADME specialists from Pharmaron and Quotient Sciences discusses key considerations for study design and execution, drawing on insights from non-clinical and clinical programs. The session covers radiosynthesis considerations, including what is possible, easy, hard and not likely with 14C radiosynthesis and best practices for maintaining radiochemical purity and stability while minimising degradation; 14C ADME studies spanning non-clinical ADME and clinical mass balance; and clinical metabolism study design and dose. Ray Cooke moderates.]]></video:description>
			<video:duration>3370</video:duration>
			<video:family_friendly>no</video:family_friendly>
			<video:uploader info="https://www.pharmaron.com/blog/author/lee-asplund/">Lee Asplund</video:uploader>
		</video:video>
	</url>
	<url>
		<loc>https://www.pharmaron.com/knowledge-center/dmpk-webinar-14-complex-ddi/</loc>
		<video:video>
			<video:title><![CDATA[The Nasty Surprise of a Complex Drug-drug Interaction (DDI)]]></video:title>
			<video:publication_date>2026-03-17T18:29:00-07:00</video:publication_date>
			<video:description><![CDATA[DMPK Webinar Series episode 14, recorded in February 2023 and available on demand. Pharmaron and University of Manchester experts discuss how in vitro studies, preclinical models, endogenous biomarkers and physiologically based pharmacokinetic (PBPK) modelling identify complex drug-drug interaction (DDI) risks and inform development decisions. Complex DDIs can involve reversible or time-dependent inhibition, induction, enzyme-transporter interplay and metabolite-mediated interactions occurring at once, so a single assay rarely predicts the clinical outcome. The session covers why standard assays miss metabolism-dependent mechanisms and inhibitory metabolites, how PBPK and mechanistic static models integrate enzyme, transporter, physiological and clinical data, why plasma exposure may not reflect tissue exposure, how endogenous biomarkers such as coproporphyrin I support earlier transporter evaluation, what validation a model needs before it can limit clinical studies, and how assumptions about CYP3A4 development change paediatric DDI predictions. The repaglinide, gemfibrozil and itraconazole example shows combined CYP2C8 and CYP3A4 inhibition raising exposure nineteenfold. Danxi Li moderates.]]></video:description>
			<video:duration>3317</video:duration>
			<video:family_friendly>no</video:family_friendly>
			<video:uploader info="https://www.pharmaron.com/blog/author/lee-asplund/">Lee Asplund</video:uploader>
		</video:video>
	</url>
	<url>
		<loc>https://www.pharmaron.com/knowledge-center/dmpk-webinar-18-protein-degraders/</loc>
		<video:video>
			<video:title><![CDATA[The DMPK Challenges and Strategies for Developing Protein Degrader Compounds]]></video:title>
			<video:publication_date>2026-03-17T18:30:00-07:00</video:publication_date>
			<video:description><![CDATA[DMPK Webinar Series episode 18, recorded in July 2023 and available on demand. Experts from Pharmaron and AstraZeneca examine how modified absorption, distribution, metabolism and excretion (ADME) assays and medicinal chemistry approaches improve data quality and aid structure optimisation for protein degraders. Protein degraders often sit outside traditional small molecule property space, where large size, lipophilicity, poor solubility, high binding and extensive metabolism can compromise assay performance, data interpretation and in vivo behaviour. The session covers how solubility, logD, protein binding, permeability, metabolism and oral bioavailability affect degraders, why poor recovery and nonspecific binding lead traditional assays to unreliable results, how assay conditions and interpretation can be adapted for degrader-like compounds, what metabolite profiles and linker cleavage mean for potency, and how to assess degrader developability early with integrated ADME workflows. Chris Bode moderates.]]></video:description>
			<video:duration>3364</video:duration>
			<video:family_friendly>no</video:family_friendly>
			<video:uploader info="https://www.pharmaron.com/blog/author/lee-asplund/">Lee Asplund</video:uploader>
		</video:video>
	</url>
	<url>
		<loc>https://www.pharmaron.com/knowledge-center/dmpk-webinar-17-pkpd/</loc>
		<video:video>
			<video:title><![CDATA[PK/PD Concepts and Applications for Effective Drug Design: Building the Translational Bridge]]></video:title>
			<video:publication_date>2026-03-17T18:30:00-07:00</video:publication_date>
			<video:description><![CDATA[DMPK Webinar Series episode 17, recorded in May 2023 and available on demand. Neil Benson and Simon Taylor introduce the principles behind pharmacokinetic and pharmacodynamic (PK/PD) modelling and explain how mathematical models connect drug exposure with efficacy, biomarkers and safety. The session covers why response to a drug is more than dose alone, why pharmacodynamics is not dictated by the pharmacokinetic profile, how direct-effect, Emax and indirect-effect models describe different response patterns, how delayed responses and hysteresis affect efficacy and safety assessment, and how population variability and data averaging influence conclusions. A drug discovery case study shows how preclinical efficacy and safety models were combined with human pharmacokinetic predictions to support clinical dose selection, therapeutic index assessment and Phase I study design. Chris Bode moderates.]]></video:description>
			<video:duration>3331</video:duration>
			<video:family_friendly>no</video:family_friendly>
			<video:uploader info="https://www.pharmaron.com/blog/author/lee-asplund/">Lee Asplund</video:uploader>
		</video:video>
	</url>
	<url>
		<loc>https://www.pharmaron.com/services/ocular-testing-services/</loc>
		<video:video>
			<video:title><![CDATA[Pharmaron San Diego Site Tour]]></video:title>
			<video:description><![CDATA[A brief tour of Pharmaron's San Diego facility supporting ocular testing and related services.]]></video:description>
			<video:thumbnail_loc>https://www.pharmaron.com/wp-content/uploads/2025/06/ocular-testing-services-650x450.webp</video:thumbnail_loc>
			<video:family_friendly>no</video:family_friendly>
			<video:uploader info="https://www.pharmaron.com/blog/author/lee-asplund/">Lee Asplund</video:uploader>
		</video:video>
	</url>
	<url>
		<loc>https://www.pharmaron.com/knowledge-center/drug-discovery-webinar-series/</loc>
		<video:video>
			<video:title><![CDATA[Macrocycles: An Increasingly Popular Strategy In Drug Design]]></video:title>
			<video:publication_date>2024-12-11T18:00:00-05:00</video:publication_date>
			<video:description><![CDATA[Episode one of the Drug Discovery Webinar Series introduces macrocyclic drugs and the advantages they hold over their acyclic counterparts, then works through rational design strategies and the physicochemical property principles that govern macrocycle optimization. The session closes with a case study on the discovery of novel PKC theta inhibitors that held potency and isoform selectivity through lead optimization.]]></video:description>
			<video:thumbnail_loc>https://www.pharmaron.com/wp-content/uploads/2024/10/400-KC-IDD-webinar-Macrocycles-cover.webp</video:thumbnail_loc>
			<video:duration>3762</video:duration>
			<video:family_friendly>no</video:family_friendly>
			<video:uploader info="https://www.pharmaron.com/blog/author/lee-asplund/">Lee Asplund</video:uploader>
		</video:video>
		<video:video>
			<video:title><![CDATA[Part 1: Discovery and Optimization of Molecular Glues: Concepts and Case Studies]]></video:title>
			<video:publication_date>2025-06-18T23:38:00-05:00</video:publication_date>
			<video:description><![CDATA[Episode two opens a two-part treatment of molecular glue degraders, covering their history, their mechanisms of action and their translational potential. Case studies cover hit identification by biophysical methods for stabilization of the SLP76 and 14-3-3 protein-protein interaction, and the rational design of novel DCAF16-recruiting BRD9 targeted glue degraders.]]></video:description>
			<video:thumbnail_loc>https://www.pharmaron.com/wp-content/uploads/2025/03/400-KC-drug-discovery-webinar2-molecular-glues-cover-on-demand.webp</video:thumbnail_loc>
			<video:duration>3079</video:duration>
			<video:family_friendly>no</video:family_friendly>
			<video:uploader info="https://www.pharmaron.com/blog/author/lee-asplund/">Lee Asplund</video:uploader>
		</video:video>
		<video:video>
			<video:title><![CDATA[Part 2: Molecular Glues: Case Studies and Future Perspectives]]></video:title>
			<video:publication_date>2025-09-25T20:46:00-05:00</video:publication_date>
			<video:description><![CDATA[Episode three follows molecular glue degrader programs from early discovery hits through to clinical candidate. The session covers CK1 alpha degrader discovery, novel assay approaches for hit identification, and the technologies now emerging in the field.]]></video:description>
			<video:thumbnail_loc>https://www.pharmaron.com/wp-content/uploads/2025/08/400-KC-idd-webinar-3-molecular-glues-pt2-cover.webp</video:thumbnail_loc>
			<video:duration>3227</video:duration>
			<video:family_friendly>no</video:family_friendly>
			<video:uploader info="https://www.pharmaron.com/blog/author/lee-asplund/">Lee Asplund</video:uploader>
		</video:video>
		<video:video>
			<video:title><![CDATA[Direct-to-Biology Services: A Contemporary Approach to Accelerate Drug Discovery]]></video:title>
			<video:publication_date>2026-04-28T20:54:00-05:00</video:publication_date>
			<video:description><![CDATA[Episode four covers how a direct-to-biology approach shortens the design-make-test cycle in drug discovery. The session sets out the benefits of direct-to-biology, walks through typical high-throughput workflows using internally generated data on bifunctional degraders, and closes with a case study on the discovery of a CNS-active GSK3 degrader.]]></video:description>
			<video:thumbnail_loc>https://www.pharmaron.com/wp-content/uploads/2026/03/dd-web-4-Direct-to-Biology-on-demand-cover.webp</video:thumbnail_loc>
			<video:duration>3281</video:duration>
			<video:family_friendly>no</video:family_friendly>
			<video:uploader info="https://www.pharmaron.com/blog/author/lee-asplund/">Lee Asplund</video:uploader>
		</video:video>
	</url>
	<url>
		<loc>https://www.pharmaron.com/knowledge-center/bioinnovate-webinar-18-aav-production/</loc>
		<video:video>
			<video:title><![CDATA[AAV Production Process Intensification Using Perfusion Bioreactor Technology]]></video:title>
			<video:publication_date>2026-06-23T21:37:00-07:00</video:publication_date>
			<video:description><![CDATA[BioInnovate Webinar Series Episode 18 (recorded June 22, 2026). An Innovate UK-funded collaboration covering strategies for upstream AAV intensification, high-cell-density transfection, scale-up considerations, and downstream purification for viral vector manufacturing. Moderated by Paul Young (Pharmaron), with speakers Mustafa Munye (Complement Therapeutics), Juline Guenat (Cell and Gene Therapy Catapult), and Taelor Patterson (Pharmaron).]]></video:description>
			<video:thumbnail_loc>https://www.pharmaron.com/wp-content/uploads/2026/06/bioinnovate-webinar-18-on-demand-cover.webp</video:thumbnail_loc>
			<video:duration>3424</video:duration>
			<video:family_friendly>no</video:family_friendly>
			<video:uploader info="https://www.pharmaron.com/blog/author/lee-asplund/">Lee Asplund</video:uploader>
		</video:video>
	</url>
	<url>
		<loc>https://www.pharmaron.com/knowledge-center/macrocyclic-drug-discovery/</loc>
		<video:video>
			<video:title><![CDATA[Identification of Novel Macrocyclic Inhibitors of the Polymerase Domain of DNA Polymerase Theta]]></video:title>
			<video:publication_date>2026-07-27T09:24:00-07:00</video:publication_date>
			<video:description><![CDATA[Gated on-demand presentation from an integrated drug discovery collaboration between NewBay and Pharmaron. Mark Andrews describes a macrocyclic drug discovery program that delivered potent inhibitors of the polymerase domain of DNA polymerase theta, covering how macrocyclization improved potency while generating mixtures of atropisomers, how an (R)-methyl group stabilized the active conformation, the identification of compound 1 as the leading lactam diol, the solubility limits of simplified macrocyclic inhibitors, the favorable property balance achieved with acidic sidechains and tetrazole 42, the absence of efficacy for co-dosing with niraparib in a BRCA-deficient xenograft model, and the program's subsequent shift toward more potent helicase domain inhibitors.]]></video:description>
			<video:duration>1518</video:duration>
			<video:family_friendly>no</video:family_friendly>
			<video:uploader info="https://www.pharmaron.com/blog/author/lee-asplund/">Lee Asplund</video:uploader>
		</video:video>
	</url>
	<url>
		<loc>https://www.pharmaron.com/knowledge-center/cgt-potency-assays/</loc>
		<video:video>
			<video:title><![CDATA[CGT Potency Assays: Real Challenges, Real Solutions, Real Impacts]]></video:title>
			<video:publication_date>2025-08-25T13:11:00-07:00</video:publication_date>
			<video:description><![CDATA[Gated on-demand presentation on cell and gene therapy (CGT) potency assay development. Silvia Pires Lourenco covers the questions to answer before selecting an assay platform, why multiple readouts are often required to confirm functionality, where surrogate systems fit complex disease models, and how quantitative methods such as LC-MS/MS and droplet digital PCR (ddPCR) support reproducible potency readouts.]]></video:description>
			<video:duration>632</video:duration>
			<video:family_friendly>no</video:family_friendly>
			<video:uploader info="https://www.pharmaron.com/blog/author/lee-asplund/">Lee Asplund</video:uploader>
		</video:video>
	</url>
	<url>
		<loc>https://www.pharmaron.com/knowledge-center/dmpk-webinar-32-drug-transporters/</loc>
		<video:video>
			<video:title><![CDATA[Unlocking Drug Transporters: Driving Smarter Drug Design and Development]]></video:title>
			<video:publication_date>2026-02-04T13:05:00-08:00</video:publication_date>
			<video:description><![CDATA[DMPK Webinar Series Episode 32 (recorded February 2, 2026). Explores how drug transporter studies shape absorption, distribution, and excretion and can transform drug discovery and development strategies — covering transporter expression screening for lead selection, genetic polymorphisms and transporter-mediated drug-drug interactions, and leveraging transporter insights to optimize delivery and reduce off-target toxicity. Moderated by Barry Jones (Pharmaron), with speakers Yuichi Sugiyama (ShanghaiTech University) and Chunyan Han (Pharmaron).]]></video:description>
			<video:thumbnail_loc>https://www.pharmaron.com/wp-content/uploads/2025/12/dmpk-webinar-32-on-demand.webp</video:thumbnail_loc>
			<video:family_friendly>no</video:family_friendly>
			<video:uploader info="https://www.pharmaron.com/blog/author/lee-asplund/">Lee Asplund</video:uploader>
		</video:video>
	</url>
	<url>
		<loc>https://www.pharmaron.com/knowledge-center/dmpk-webinar-36-peptides/</loc>
		<video:video>
			<video:title><![CDATA[Immunogenicity Risk Assessment: Strategies for Synthetic Peptides and Biologics]]></video:title>
			<video:publication_date>2026-06-30T20:52:00-07:00</video:publication_date>
			<video:description><![CDATA[DMPK Webinar Series Episode 36 (recorded June 28, 2026). Explores how early, orthogonal immunogenicity risk assessments — combining in vitro and in silico approaches and human-relevant new approach methodologies (NAMs) — strengthen decision-making and de-risk development of synthetic peptides and biologics ahead of first-in-human studies. Presented by George Hristopoulos and moderated by Brittany Timmons (Pharmaron).]]></video:description>
			<video:thumbnail_loc>https://www.pharmaron.com/wp-content/uploads/2026/05/DMPK-Webinar-36-on-demand-cover.webp</video:thumbnail_loc>
			<video:family_friendly>no</video:family_friendly>
			<video:uploader info="https://www.pharmaron.com/blog/author/lee-asplund/">Lee Asplund</video:uploader>
		</video:video>
	</url>
	<url>
		<loc>https://www.pharmaron.com/knowledge-center/cmc-webinar-2-jet-milling/</loc>
		<video:video>
			<video:title><![CDATA[Jet Milling in Pharma R&amp;D: Insights into Robust Micronisation Process Development]]></video:title>
			<video:publication_date>2026-07-09T11:27:00-07:00</video:publication_date>
			<video:description><![CDATA[CMC Webinar Series Episode 2 (recorded July 8, 2026). Covers jet milling process mechanics, identifying and resolving common operational challenges, and real-world case studies for robust micronisation and particle size control. Moderated by Robin Bodicoat (Pharmaron), with speakers Thoralf Hartwig and Filip Horvath-Gerber (Pharmaron).]]></video:description>
			<video:thumbnail_loc>https://www.pharmaron.com/wp-content/uploads/2026/05/cmc-webinar-2-on-demand-cover.webp</video:thumbnail_loc>
			<video:family_friendly>no</video:family_friendly>
			<video:uploader info="https://www.pharmaron.com/blog/author/lee-asplund/">Lee Asplund</video:uploader>
		</video:video>
	</url>
	<url>
		<loc>https://www.pharmaron.com/knowledge-center/dmpk-webinar-35-covalent-inhibitors/</loc>
		<video:video>
			<video:title><![CDATA[Cracking the PK/PD Code for Targeted Covalent Inhibitors]]></video:title>
			<video:publication_date>2026-05-28T14:10:00-07:00</video:publication_date>
			<video:description><![CDATA[On-demand recording of Pharmaron DMPK Webinar Series Episode 35 featuring Upendra Dahal and Nashid Farhan from Amgen, moderated by Nicolas Duchemin from Pharmaron.]]></video:description>
			<video:thumbnail_loc>https://www.pharmaron.com/wp-content/uploads/2026/04/dmpk-webinar-35-on-demand-cover-640x360.webp</video:thumbnail_loc>
			<video:content_loc>https://www.pharmaron.com/knowledge-center/dmpk-webinar-35-covalent-inhibitors/</video:content_loc>
			<video:duration>5400</video:duration>
			<video:family_friendly>no</video:family_friendly>
			<video:uploader info="https://www.pharmaron.com/blog/author/lee-asplund/">Lee Asplund</video:uploader>
		</video:video>
	</url>
	<url>
		<loc>https://www.pharmaron.com/knowledge-center/bioinnovate-series-15-elispot-bioanalytical-testing/</loc>
		<video:video>
			<video:title><![CDATA[Use of ELISpot and Fluorospot in Bioanalytical Testing]]></video:title>
			<video:description><![CDATA[Explore bioanalytical testing with ELISpot capabilities and RAWSpot technology for multiplex cytokine analysis and immunogenicity screening.]]></video:description>
			<video:player_loc>https://videos.pharmaron.com/watch/A4HAcLOLOO68!AENDWtckf4bl</video:player_loc>
			<video:thumbnail_loc>https://www.pharmaron.com/wp-content/uploads/2024/12/400-KC-cgt-webinar-15-on-demand-elispot.webp</video:thumbnail_loc>
			<video:family_friendly>no</video:family_friendly>
			<video:uploader info="https://www.pharmaron.com/blog/author/lee-asplund/">Lee Asplund</video:uploader>
		</video:video>
	</url>
	<url>
		<loc>https://www.pharmaron.com/about-us/locations/nanjing/</loc>
		<video:video>
			<video:title><![CDATA[Nanjing | Pharmaron]]></video:title>
			<video:description><![CDATA[Enjoy the videos and music you love, upload original content, and share it all with friends, family, and the world on YouTube.]]></video:description>
			<video:player_loc>https://www.youtube.com/embed/ScMzIvxBSi4</video:player_loc>
			<video:thumbnail_loc>https://www.pharmaron.com/wp-content/uploads/2022/01/pharmaron-nanjing-site.webp</video:thumbnail_loc>
			<video:family_friendly>yes</video:family_friendly>
			<video:uploader info="https://www.pharmaron.com/blog/author/lee-asplund/">Lee Asplund</video:uploader>
		</video:video>
	</url>
	<url>
		<loc>https://www.pharmaron.com/knowledge-center/key-concepts-for-medical-device-testing/</loc>
		<video:video>
			<video:title><![CDATA[Key Concepts for Medical Device Testing (On-Demand Webinar)]]></video:title>
			<video:publication_date>2023-07-30T00:00:00-05:00</video:publication_date>
			<video:description><![CDATA[Gated, on-demand webinar on preclinical medical device testing with emphasis on in vivo study design, large animal model selection, and practical considerations for generating credible data for regulatory pathways.]]></video:description>
			<video:thumbnail_loc>https://www.pharmaron.com/wp-content/uploads/2023/07/medical-device-webinar-key-concents-testing-1024x576.webp</video:thumbnail_loc>
			<video:family_friendly>no</video:family_friendly>
			<video:uploader info="https://www.pharmaron.com/blog/author/lee-asplund/">Lee Asplund</video:uploader>
		</video:video>
	</url>
	<url>
		<loc>https://www.pharmaron.com/knowledge-center/cgt-ind-bla-strategy/</loc>
		<video:video>
			<video:title><![CDATA[CGT IND/BLA Strategy: Paths to Gene Therapy Approval]]></video:title>
			<video:description><![CDATA[Gated on-demand presentation on CGT CMC strategy from IND planning through process validation and BLA/MAA submission readiness, including platform-based approaches, assay strategy and regulatory alignment.]]></video:description>
			<video:thumbnail_loc>https://www.pharmaron.com/wp-content/uploads/2025/12/cgt-potency-assays-sapa2025-640x360.webp</video:thumbnail_loc>
			<video:family_friendly>no</video:family_friendly>
			<video:uploader info="https://www.pharmaron.com/blog/author/lee-asplund/">Lee Asplund</video:uploader>
		</video:video>
	</url>
	<url>
		<loc>https://www.pharmaron.com/knowledge-center/dmpk-webinar-28-hadme-studies/</loc>
		<video:video>
			<video:title><![CDATA[DMPK Webinar 28: Accelerator Mass Spectrometry in hADME – Recent and Future Advances (On-Demand)]]></video:title>
			<video:publication_date>2025-07-30T14:25:00-07:00</video:publication_date>
			<video:description><![CDATA[Watch our on-demand webinar on AMS in hADME Studies, exploring Ionplus LEA, CO₂ interfaced AMS, and future ADME innovations.]]></video:description>
			<video:player_loc>https://www.pharmaron.com/knowledge-center/dmpk-webinar-28-hadme-studies/</video:player_loc>
			<video:thumbnail_loc>https://www.pharmaron.com/wp-content/uploads/2025/07/400-KC-dmpk-webinar-28-AMS-hADME.webp</video:thumbnail_loc>
			<video:content_loc>https://www.pharmaron.com/knowledge-center/dmpk-webinar-28-hadme-studies/</video:content_loc>
			<video:duration>3600</video:duration>
			<video:family_friendly>no</video:family_friendly>
			<video:uploader info="https://www.pharmaron.com/blog/author/lee-asplund/">Lee Asplund</video:uploader>
		</video:video>
	</url>
</urlset>
<!-- XML Sitemap generated by Rank Math SEO Plugin (c) Rank Math - rankmath.com -->